Abstract
Portal vein embolisation (PVE) is used to increase the remnant liver volume before major liver resection for colorectal metastases. The resection rate after PVE is 60-70%, mainly limited by disease progression. The effect of PVE on tumour growth rate has not been investigated. The objective of this study was to compare the growth characteristics of resected colorectal liver metastases in patients undergoing pre-operative PVE with those of matched controls who had not undergone PVE. There were 22 patients who had undergone preoperative PVE and 20 matched controls. Tumour growth rate was calculated by the change in tumour volume (CT/MRI volumetric assessment) from diagnosis to resection. Resected histological specimens were examined by two histopathologists independently for cell differentiation, percentage tumour cell necrosis and mitotic rate. Immunochemical staining with Ki67 was carried out using the MIB-1 monoclonal antibody and quantified using a Glasgow cell-counting graticule. The groups were comparable in demographics, stage of primary disease, volume of liver metastases at presentation and chemotherapy received. The tumour growth rate calculated from imaging was more rapid in the PVE group compared with that in controls (control: 0.05±0.25 ml day-1, PVE: 0.36±0.68 ml day-1, P=0.06). Histology showed no difference in the degree of differentiation, extent of necrosis or apoptosis between the two groups. However, mitotic rate was higher post PVE, as was the proliferation index Ki67 (P=0.04). This study has confirmed that tumour growth rate increased following PVE and that this is related to increased tumour cell division.
| Original language | English |
|---|---|
| Pages (from-to) | 617-622 |
| Number of pages | 6 |
| Journal | British Journal of Cancer |
| Volume | 100 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Feb 24 2009 |
Fingerprint
Keywords
- Colorectal liver metastases
- Liver resection
- Portal vein embolisation
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Effect of portal vein embolisation on the growth rate of colorectal liver metastases. / Pamecha, V.; Levene, A.; Grillo, F.; Woodward, N.; Dhillon, A.; Davidson, B. R.
In: British Journal of Cancer, Vol. 100, No. 4, 24.02.2009, p. 617-622.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of portal vein embolisation on the growth rate of colorectal liver metastases
AU - Pamecha, V.
AU - Levene, A.
AU - Grillo, F.
AU - Woodward, N.
AU - Dhillon, A.
AU - Davidson, B. R.
PY - 2009/2/24
Y1 - 2009/2/24
N2 - Portal vein embolisation (PVE) is used to increase the remnant liver volume before major liver resection for colorectal metastases. The resection rate after PVE is 60-70%, mainly limited by disease progression. The effect of PVE on tumour growth rate has not been investigated. The objective of this study was to compare the growth characteristics of resected colorectal liver metastases in patients undergoing pre-operative PVE with those of matched controls who had not undergone PVE. There were 22 patients who had undergone preoperative PVE and 20 matched controls. Tumour growth rate was calculated by the change in tumour volume (CT/MRI volumetric assessment) from diagnosis to resection. Resected histological specimens were examined by two histopathologists independently for cell differentiation, percentage tumour cell necrosis and mitotic rate. Immunochemical staining with Ki67 was carried out using the MIB-1 monoclonal antibody and quantified using a Glasgow cell-counting graticule. The groups were comparable in demographics, stage of primary disease, volume of liver metastases at presentation and chemotherapy received. The tumour growth rate calculated from imaging was more rapid in the PVE group compared with that in controls (control: 0.05±0.25 ml day-1, PVE: 0.36±0.68 ml day-1, P=0.06). Histology showed no difference in the degree of differentiation, extent of necrosis or apoptosis between the two groups. However, mitotic rate was higher post PVE, as was the proliferation index Ki67 (P=0.04). This study has confirmed that tumour growth rate increased following PVE and that this is related to increased tumour cell division.
AB - Portal vein embolisation (PVE) is used to increase the remnant liver volume before major liver resection for colorectal metastases. The resection rate after PVE is 60-70%, mainly limited by disease progression. The effect of PVE on tumour growth rate has not been investigated. The objective of this study was to compare the growth characteristics of resected colorectal liver metastases in patients undergoing pre-operative PVE with those of matched controls who had not undergone PVE. There were 22 patients who had undergone preoperative PVE and 20 matched controls. Tumour growth rate was calculated by the change in tumour volume (CT/MRI volumetric assessment) from diagnosis to resection. Resected histological specimens were examined by two histopathologists independently for cell differentiation, percentage tumour cell necrosis and mitotic rate. Immunochemical staining with Ki67 was carried out using the MIB-1 monoclonal antibody and quantified using a Glasgow cell-counting graticule. The groups were comparable in demographics, stage of primary disease, volume of liver metastases at presentation and chemotherapy received. The tumour growth rate calculated from imaging was more rapid in the PVE group compared with that in controls (control: 0.05±0.25 ml day-1, PVE: 0.36±0.68 ml day-1, P=0.06). Histology showed no difference in the degree of differentiation, extent of necrosis or apoptosis between the two groups. However, mitotic rate was higher post PVE, as was the proliferation index Ki67 (P=0.04). This study has confirmed that tumour growth rate increased following PVE and that this is related to increased tumour cell division.
KW - Colorectal liver metastases
KW - Liver resection
KW - Portal vein embolisation
UR - http://www.scopus.com/inward/record.url?scp=60349121016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60349121016&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6604872
DO - 10.1038/sj.bjc.6604872
M3 - Article
C2 - 19209170
AN - SCOPUS:60349121016
VL - 100
SP - 617
EP - 622
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 4
ER -